Illinois warns 340B expansion cost

Illinois officials are warning that a bill moving through Springfield could add millions of dollars to public and private healthcare costs by expanding how safety-net providers use the federal 340B drug discount program. A May 12 memo from the Illinois Department of Central Management Services estimated the proposal could cost Illinois employers an additional $89 million a year, including more than $12 million for the state employee health plan, according to Capitol News Illinois. House Bill 2371, as amended in the Senate, would bar drug manufacturers from limiting deliveries of 340B-priced medicines to contract pharmacies used by eligible hospitals and clinics. The measure would also bar manufacturers from demanding certain pricing, ingredient-cost and inventory data unless state or federal law requires it. (nprillinois.org) The fight in Illinois is part of a broader national dispute over 340B, a 1992 federal program that requires drugmakers to sell outpatient medicines at discounted prices to certain hospitals and clinics serving low-income, rural and uninsured patients. HRSA, the federal agency that oversees 340B, is separately reconsidering whether to allow a rebate-based model in the program after a federal court vacated an earlier pilot and sent it back to the agency. (nprillinois.org) ### Why are Illinois officials saying the bill could cost money? The May 12 memo said expanding contract-pharmacy access under the Illinois bill could raise prescription-drug spending for employers that fund health coverage, according to Capitol News Illinois. The estimate cited by the outlet put the statewide employer impact at $89 million a year and the direct state share at more than $12 million. (federalregister.gov) The legislation is aimed at manufacturer restrictions that hospitals, federally qualified health centers and Ryan White clinics say have cut off their ability to obtain 340B-priced drugs through outside pharmacy partners. Supporters say those contract pharmacies are often how patients in rural areas or places without in-house dispensaries actually receive medicines. (nprillinois.org) ### What exactly would the Illinois bill do? Senate Bill 2385, introduced by state Senator David Koehler, would prohibit a manufacturer from denying, restricting or otherwise interfering with the acquisition or delivery of a 340B drug to a covered entity or its authorized contract pharmacy, unless federal law bars that receipt. The bill text also says manufacturers could not limit the number, location, ownership or type of contract pharmacy a covered entity uses. (nprillinois.org) The bill text further says manufacturers could not require submission of ingredient-cost or pricing data, impose inventory-management requirements not required by government agencies, or demand other data as a condition of 340B participation. LegiScan shows the measure was re-referred to assignments on June 2, 2025, and Capitol News Illinois reported the House measure was awaiting a final vote. ### Why is 340B drawing this much scrutiny? (legiscan.com) The 340B program lets covered entities buy eligible outpatient drugs at steep discounts and then bill insurers at higher rates, creating a spread that providers say helps fund uncompensated care and other services. Capitol News Illinois described that spread as an indirect revenue stream for participating facilities. (legiscan.com) Minnesota has become one of the few states publishing detailed data on the program. A Minnesota Department of Health report covered by STAT said hospitals and clinics in that state received $3.045 billion in discounted medicines in 2024, paid about $1.53 billion plus $165 million in administrative fees, and generated at least $1.34 billion in revenue; the largest hospitals received more than $1 billion, or 80% of the total. (nprillinois.org) ### What is happening at the federal level? HRSA said on its 340B program page that a U.S. District Court in Maine vacated and remanded the agency’s 2025 rebate-model pilot notices on February 10, 2026. The agency said it is reconsidering whether to implement a 340B Rebate Model Pilot Program consistent with its statutory authority. A February 17, 2026 notice in the Federal Register said HRSA was seeking input on whether it should use rebates to deliver the 340B ceiling price and how such a framework would affect covered entities, manufacturers and other parts of the drug supply chain. (statnews.com) HRSA said the comment period later closed on April 20 and that it is reviewing comments and determining next steps. (hrsa.gov) ### Where does the global price-transparency debate fit in? WHO says the 79th World Health Assembly will meet in Geneva from May 18 to May 23, 2026, and the organization continues to frame medicine-price transparency as part of its affordability work. WHO also maintains public medicine-price information resources linked to the 2019 World Health Assembly resolution on improving transparency in markets for medicines, vaccines and other health products. (federalregister.gov) The Illinois dispute is unfolding as policymakers in the United States and abroad keep pressing drug-pricing systems for more disclosure. In Illinois, the next concrete step is legislative: Capitol News Illinois reported House Bill 2371 was awaiting a final House vote, while HRSA said it is still reviewing comments on its federal 340B rebate-model request for information. (nprillinois.org) (who.int)